

## ABSTRACT OF THE DISCLOSURE

The present invention provides method of treating uterine serous papillary carcinoma in an individual in need of such treatment, comprising the step of administering to said individual a therapeutically effective dose of a HER-2/neu antibody. Also provided is a method of differentiating primary uterine serous papillary carcinoma from serous papillary ovarian tumors in an individual, comprising the step of measuring the expression of HER-2/neu in said tissue, wherein the presence of an increased and constitutive expression pattern in said tissue indicates that said tumor is a uterine serous papillary carcinoma. Further provided is a method of treating uterine serous papillary carcinoma in an individual in need of such treatment, comprising the step of administering to said individual a therapeutically effective dose of a HER-2/neu antibody and a therapeutically effective dose of interleukin-2.